Cutting edge developments and novel targets in IBD: Microbiome in IBD.

Area of Science:

• Gastroenterology and Microbiology
• Immunology and Inflammation Research

Background:

• Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic condition with rising prevalence and intricate causes.
• The gut microbiome is increasingly recognized for its significant role in IBD development and progression.
• This has spurred significant interest in developing therapies that target the gut's microbial community.

Purpose of the Study:

• To provide a comprehensive overview of current research on microbiome modulation for IBD.
• To examine various therapeutic strategies aimed at restoring microbial balance in IBD patients.
• To explore the potential of non-bacterial microbiota and lifestyle factors in IBD management.

Main Methods:

• This narrative review synthesizes recent scientific literature on microbiome-targeted therapies for IBD.
• It covers a range of interventions, including antibiotics, prebiotics, probiotics, synbiotics, and fecal microbiota transplantation.
• The review also considers dietary changes, physical activity, and the roles of fungi, archaea, and bacteriophages.

Main Results:

• Emerging evidence supports the efficacy of various microbiome modulation techniques in IBD.
• Restoring microbial equilibrium is crucial for mitigating intestinal inflammation.
• A combination of therapies may be necessary for optimal IBD management.

Conclusions:

• Microbiome-targeted therapies represent a promising frontier in IBD treatment.
• Integrating these approaches with lifestyle modifications and conventional treatments may lead to personalized IBD management strategies.
• Further research is needed to fully elucidate the potential of these novel therapeutic avenues.